EPYSQLI

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, United Kingdom, United States

Active ingredients

The drug EPYSQLI contains one active pharmaceutical ingredient (API):

1 Eculizumab UNII A3ULP0F556 - ECULIZUMAB

Eculizumab is a monoclonal antibody, a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes. Read about Eculizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AJ01	Eculizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3036899
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1231735001
Country: FR	Base de données publique des médicaments	Identifier(s): 67665594
Country: IT	Agenzia del Farmaco	Identifier(s): 050699014
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097177
Country: US	FDA, National Drug Code	Identifier(s): 71202-010